- Home
- Automated
- List of product information
- DUROMINE CAPSULE 15 MG [SIN01255P]
DUROMINE CAPSULE 15 MG [SIN01255P]
Active ingredients: DUROMINE CAPSULE 15 MG
Product Info
DUROMINE CAPSULE 15 MG
[SIN01255P]
Product information
Active Ingredient and Strength | PHENTERMINE ION-EXCHANGE RESIN COMPLEX EQV PHENTERMINE - 15 MG |
Dosage Form | CAPSULE |
Manufacturer and Country | DOUGLAS MANUFACTURING LTD - NEW ZEALAND |
Registration Number | SIN01255P |
Licence Holder | INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | A08AA01 |
INDICATIONS
Duromine is an anorectic agent indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based, for example, on exercise, diet (caloric/kilojoule restriction) and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m2 or greater. The treatment with Duromine can be initiated in overweight patients with a lower BMI (25 to 29.9 kg/m2) which increases the risk of morbidity from a number of disorders. Secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.
DOSAGE AND ADMINISTRATION
Adults and children over 12 years:
One capsule daily at breakfast, swallowed whole. Evening dosing should be avoided, as this agent may induce insomnia. It is recommended that treatment should be initiated under the care of physicians experienced in the treatment of obesity.
The recommended starting dose is 30mg daily. The recommended maintenance dose, either continuous or intermittent is 15 to 30 mg daily depending on responsiveness. The recommended dose of Duromine should not be exceeded to increase the effect. Duromine should not be combined with other appetite suppressants. Patients require medical review after a defined course of treatment, which should not exceed three months.
Children under 12 years:
Duromine is not recommended for children under the age of twelve.
Elderly:
Duromine is not recommended for the elderly.
CONTRAINDICATIONS
Pulmonary artery hypertension; existing heart valve abnormalities or heart murmurs; moderate to severe arterial hypertension; cerebro-vascular disease; severe cardiac disease including arrhythmias, advanced arteriosclerosis; known hypersensitivity to sympathomimetic drugs; hyperthyroidism; agitated states or a history of psychiatric illnesses including anorexia nervosa and depression; glaucoma; history of drug/ alcohol abuse or dependence; concomitant treatment with Monoamine Oxidase (MAO) Inhibitors or within 14 days following their administration.
